CureVac NV (CVAC)
4.66
0.00 (0.00%)
USD |
NASDAQ |
Jun 10, 16:00
CureVac Debt to Equity Ratio : 0.0403 for Sept. 30, 2025
Debt to Equity Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2025 | 0.0402 |
| June 30, 2025 | 0.0614 |
| March 31, 2025 | 0.0578 |
| December 31, 2024 | 0.0559 |
| September 30, 2024 | 0.0554 |
| June 30, 2024 | 0.1037 |
| March 31, 2024 | 0.0909 |
| December 31, 2023 | 0.0809 |
| September 30, 2023 | 0.0699 |
| June 30, 2023 | 0.0624 |
| March 31, 2023 | 0.0577 |
| December 31, 2022 | 0.0789 |
| Date | Value |
|---|---|
| September 30, 2022 | 0.066 |
| June 30, 2022 | 0.0645 |
| March 31, 2022 | 0.0602 |
| December 31, 2021 | 0.042 |
| September 30, 2021 | 0.0813 |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 0.0777 |
| September 30, 2020 | 0.0403 |
| June 30, 2020 | |
| March 31, 2020 | -2.279 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Debt to Equity Ratio Benchmarks
| PAION AG | -- |
| Epigenomics AG | -- |
| ACADIA Pharmaceuticals, Inc. | 0.0407 |
| Alkermes Plc | 0.903 |
| Alnylam Pharmaceuticals, Inc. | 2.762 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 1.338B |
| Total Liabilities (Quarterly) | 314.18M |
| Shareholders Equity (Quarterly) | 1.024B |
| Current Ratio | 3.697 |
| Net Debt Paydown Yield | 0.01% |